October 4, 2024
Palliative care has proven to be one of the most promising fields for research on interventions with psychedelic substances. One of the most prominent researchers in […]
October 4, 2024
TOPLINE: Prehospital opioid overdoses among young people increased sharply during the COVID-19 pandemic, with 86.7% cases occurring in young adults aged 18-24 years, a new study […]
September 30, 2024
Clozapine is considered the drug of choice for treatment-resistant schizophrenia in guidelines globally, but it remains significantly underutilized. This is largely due to its range of […]
September 30, 2024
MILAN — Antidepressants escitalopram and duloxetine have been shown to improve verbal memory in moderate to severe depression, a clinical effect linked to changes in serotonin […]
September 27, 2024
The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed […]
September 27, 2024
MILAN — Pregnant women with heightened amygdala activity have a reduced capacity to regulate emotions and report more symptoms of depression than those with lower activity […]
September 27, 2024
Semaglutide (Ozempic, Novo Nordisk) is associated with a significantly lower risk for overdose in individuals with opioid use disorder (OUD), new research shows. The findings suggest […]
September 27, 2024
MILAN, Italy — Tapering antipsychotic medication for patients in remission after first episode psychosis (FEP) may be challenging in the short term but beneficial over the […]
September 27, 2024
MILAN — Specific combinations of hormonal and biochemical factors were associated with different clinical characteristics and treatment outcomes of alcohol use disorder (AUD) between men and […]